CLINICAL TRIALS PROFILE FOR MPI DTPA KIT - CHELATE

All Clinical Trials for MPI DTPA KIT - CHELATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00440583 ↗	The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP	Completed	Bayer	Phase 2	2006-09-01	The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.
NCT00440583 ↗	The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP	Completed	Mahidol University	Phase 2	2006-09-01	The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.
NCT00461149 ↗	Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly	Completed	Federico II University	Phase 4	1995-01-01	Epidemiological data indicate that patients with active acromegaly have reduced life expectancy because of cardiovascular (60%) and respiratory diseases (25%) mainly (1-10). A post-treatment GH value
NCT00602316 ↗	Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer	Unknown status	Royal Marsden NHS Foundation Trust	N/A	2007-11-01	RATIONALE: Diagnostic procedures, such as multifunctional magnetic resonance imaging, may help doctors learn the extent of disease and plan the best treatment. PURPOSE: This clinical trial is studying how well multifunctional magnetic resonance imaging works in predicting breast lesions in women undergoing mastectomy for breast cancer.
NCT01059474 ↗	Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion	Completed	Phoenix Children's Hospital	Phase 1	2010-04-01	DMPS is a metal chelator which is approved for use in Europe. While not an FDA-approved drug in the US, it is easily obtained and administered by alternative health practitioners to their patients. A formulation called 'TD DMPS' (transdermal DMPS) is in use, despite the fact there is no published literature to support that the agent is absorbed transdermally. The investigators hypothesis is that DMPS is not absorbed through the skin. The investigators plan to apply TD DMPS to healthy volunteers and then test serum for presence of DMPS. In addition the investigators will measure urinary mercury concentrations pre and post DMPS application.
NCT01059474 ↗	Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion	Completed	Banner Health	Phase 1	2010-04-01	DMPS is a metal chelator which is approved for use in Europe. While not an FDA-approved drug in the US, it is easily obtained and administered by alternative health practitioners to their patients. A formulation called 'TD DMPS' (transdermal DMPS) is in use, despite the fact there is no published literature to support that the agent is absorbed transdermally. The investigators hypothesis is that DMPS is not absorbed through the skin. The investigators plan to apply TD DMPS to healthy volunteers and then test serum for presence of DMPS. In addition the investigators will measure urinary mercury concentrations pre and post DMPS application.

Clinical Trial Conditions for MPI DTPA KIT - CHELATE

Condition Name

Condition Name for MPI DTPA KIT - CHELATE
Intervention	Trials
COVID19	3
Iron Deficiency Anemia	3
COVID-19	2
Iron Deficiency Anemia of Pregnancy	1

Condition MeSH

Condition MeSH for MPI DTPA KIT - CHELATE
Intervention	Trials
COVID-19	5
Anemia, Iron-Deficiency	5
Anemia	5
Deficiency Diseases	4

Clinical Trial Locations for MPI DTPA KIT - CHELATE

Trials by Country

Trials by Country for MPI DTPA KIT - CHELATE
Location	Trials
United States	30
Japan	14
Italy	9
Germany	7
China	5

Trials by US State

Trials by US State for MPI DTPA KIT - CHELATE
Location	Trials
Missouri	3
California	3
Ohio	3
Maryland	2
South Carolina	2

Clinical Trial Progress for MPI DTPA KIT - CHELATE

Clinical Trial Phase

Clinical Trial Phase for MPI DTPA KIT - CHELATE
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	7
Phase 3	7

Clinical Trial Status

Clinical Trial Status for MPI DTPA KIT - CHELATE
Clinical Trial Phase	Trials
Completed	17
Unknown status	5
Not yet recruiting	3

Clinical Trial Sponsors for MPI DTPA KIT - CHELATE

Sponsor Name

Sponsor Name for MPI DTPA KIT - CHELATE
Sponsor	Trials
National Cancer Institute (NCI)	2
Bayer	2
Replicor Inc.	2

Sponsor Type

Sponsor Type for MPI DTPA KIT - CHELATE
Sponsor	Trials
Other	28
Industry	15
NIH	2

Last updated: July 28, 2026

MPI DTPA KIT - CHELATE clinical trials update, FDA status, exclusivity timeline, and market projection

Executive summary: MPI DTPA KIT - CHELATE (active ingredient: technetium Tc 99m pentetate; “DTPA kit” for radiopharmaceutical imaging) has a market profile tied to diagnostic utilization cycles, supply-chain continuity, and conversion to next-generation imaging modalities rather than patent-driven exclusivity cycles alone. Competitive risk is structurally higher because multiple suppliers can source kits and generator eluate, and substitution is often driven by logistics, imaging workflow compatibility, and radiopharmacy service coverage. A defensible view on launch risk, Paragraph IV probability, and patent estate strength requires Orange Book and patent-list evidence tied to the exact marketed NDA/BLA and strength/formulation.

No patent, FDA approval, or trials-identifying identifiers (NDA/BLA number, Orange Book listing, sponsor, or specific active ingredient mapping to “MPI DTPA KIT - CHELATE”) were provided, so a complete and accurate clinical/trials and patent-exclusivity and commercial-projection build cannot be produced.